semaglutide injection fda approval Approves First Treatment to Reduce Risk of Serious Heart Problems Specifically in Adults with Obesity Wegovy® | Wegovy Weight Loss

Last updated on Jun 19, 2026

Figure 9 Discussion It is challenging to formulate effective treatment options for IBS since the symptom likely represents a variety of medical conditions (36)

However, your doctor may decide that a lower maintenance dose (such as 5 mg, 10 mg, or 12.5 mg) is effective enough for you

In the Phase II obesity clinical trial MOMENTUM-1, a 2.4 mg dose of pemvidutide resulted in an average weight loss of 15.6% after 48 weeks, with the placebo-corrected figure being 13.4%

A combined outcome of steatohepatitis resolution and fibrosis improvement was achieved in 32.7% of semaglutide users and in 16.1% of the placebo group

PMID 3335535